Cardiorenal Syndromes

By the end of this chapter you should be able to:

• Classify the five cardiorenal syndromes and state which organ led in each.
• Explain why venous congestion, not low cardiac output, drives the kidney injury in most acute cardiorenal disease.
• Define the trans-renal perfusion gradient and predict how a rising central venous pressure lowers GFR.
• Assess congestion with the jugular venous pressure, lung and IVC ultrasound, venous-excess imaging, and the natriuretic response.
• Prescribe decongestion: loop diuretics dosed and delivered correctly, with a planned response check.
• Recognise and overcome diuretic resistance with escalation and sequential nephron blockade.
• Distinguish true worsening renal function from the benign pseudo-worsening of effective decongestion, and decide when to continue diuretics through a creatinine rise.
• Place inotropes, ultrafiltration, and guideline-directed heart-failure therapy correctly, and avoid giving fluid to a congested patient.

• Cardiorenal syndrome is two organs failing together: dysfunction in the heart or the kidney drives dysfunction in the other.
• Ronco's five types name which organ led — acute or chronic cardiorenal, acute or chronic renocardiac, and the secondary type from a shared systemic insult.
• The classification is conceptual; the everyday battleground is type 1 — acute decompensated heart failure with worsening renal function.
• The old model blamed low forward output, but venous congestion is the dominant driver in most acute cardiorenal disease.
• A high central venous pressure raises renal venous pressure, narrows the trans-renal perfusion gradient, and lowers GFR — the kidney is being throttled from behind.
• Central venous pressure tracks worsening renal function better than cardiac index in decompensated heart failure.
• A neurohormonal vicious cycle — renin-angiotensin, sympathetic, vasopressin — retains sodium and water and deepens the congestion.
• Abdominal congestion and raised intra-abdominal pressure add to the renal insult in the most congested patients.
• Decongestion is the cornerstone of treatment: intravenous loop diuretics, dosed at least at the home equivalent, with a urine-sodium check at two hours.
• Diuretic resistance comes from gut oedema, low GFR, neurohormonal braking, and high salt intake; overcome it by escalating the dose, switching to infusion, and blocking the nephron sequentially.
• A creatinine rise during effective decongestion is often pseudo-worsening — haemoconcentration and neurohormonal activation — and carries a good prognosis if congestion is being cleared.
• Do not reflexively stop diuretics for that rise if the patient is still congested and decongestion is working.
• Inotropes are for the low-output, cardiogenic-shock patient only; ultrafiltration is for diuretic-refractory congestion, not first-line.
• Guideline-directed heart-failure therapy protects both organs long term, and a modest creatinine rise on starting a RAAS blocker is expected, not injury.

The heart and the kidney fail in conversation. Each speaks to the other through pressure, volume, and a shared neurohormonal language, so a problem in one becomes a problem in both. The single most useful correction this chapter makes is to the intuition that a failing kidney in heart failure must be starved of forward flow. Far more often it is being throttled from behind, by the congestion the failing heart cannot clear — and that changes the treatment from giving fluid to taking it away.

Five syndromes, one question: which organ led?

The cardiorenal syndromes are a classification of direction. Type 1, acute cardiorenal, is an abrupt cardiac insult — decompensated heart failure, an acute coronary syndrome, cardiogenic shock — causing AKI. Type 2, chronic cardiorenal, is chronic heart failure grinding the kidney into CKD. Type 3, acute renocardiac, reverses the arrow: an AKI throws fluid, potassium, acid, and uraemic toxins at the heart and provokes acute cardiac dysfunction. Type 4, chronic renocardiac, is the cardiovascular burden of CKD — hypertrophy and accelerated atherosclerosis. Type 5, secondary, is a systemic disease such as sepsis or amyloidosis striking both at once. The scheme is more conceptual than prescriptive; its value is the discipline of asking which organ led, because that points to the driver. In practice, type 1 dominates the wards, and the rest of this chapter lives there.

The correction: congestion, not forward failure

The kidney perfuses on a gradient — the difference between the arterial pressure pushing blood in and the venous pressure it must push against to leave. Heart failure raises central venous pressure, which is transmitted back to the renal veins; as renal venous pressure climbs, the trans-renal gradient narrows and GFR falls, even when arterial pressure and cardiac output look adequate. The kidney is encapsulated, so congestion also raises its interstitial and tubular pressure, compounding the fall. The evidence has caught up with the physiology: in decompensated heart failure, a high central venous pressure predicts worsening renal function more reliably than a low cardiac index. Forward failure still matters at the extreme — cardiogenic shock genuinely starves the kidney — but for the typical congested patient, the problem is backward, and so is the solution.

The vicious cycle and the abdomen

Congestion is self-reinforcing. The underfilled-feeling circulation activates the renin-angiotensin system, the sympathetic nerves, and vasopressin, all of which retain sodium and water and raise venous pressure further, which worsens renal function, which activates them more. Breaking that loop is what guideline-directed heart-failure therapy does over time. There is an abdominal dimension too: ascites and gut oedema raise intra-abdominal pressure, which presses on the renal veins and parenchyma and adds its own decrement to GFR. In the most congested patients, relieving abdominal pressure improves renal function as decongestion proceeds.

Reading congestion

If congestion is the driver, congestion is what you must measure. The jugular venous pressure remains the bedside anchor; lung ultrasound B-lines and a plethoric, non-collapsing inferior vena cava extend it; and venous-excess ultrasound grades the severity of systemic venous congestion through the hepatic, portal, and intrarenal venous flow patterns. Read volume distribution, not just volume: many decompensated patients are congested through redistribution rather than gross fluid excess. The natriuretic response is the other half of the assessment — a spot urine sodium below roughly 50 to 70 mmol/L a couple of hours after a loop diuretic predicts a poor diuretic response and tells you to escalate early rather than wait a day to fail.

Decongestion: the prescription

Loop diuretics are first-line, and the common errors are timidity and the wrong route. Give them intravenously, because gut oedema cripples oral absorption, and dose at least at the patient's home oral-equivalent, often higher; a randomised comparison found higher dosing achieved more decongestion at the cost of a transient, benign creatinine rise, with little difference between bolus and continuous infusion. Then check the response rather than assume it: urine output over the next hours, and a spot urine sodium at two hours. Reassess congestion daily by the same signs you used to diagnose it, and keep going until the patient is decongested, not merely diuresing.

When the diuretic stops working

Diuretic resistance is the rule in the sick cardiorenal patient, not the exception. Gut oedema limits absorption, a low GFR limits delivery of drug to its tubular site of action, neurohormonal braking and distal sodium avidity blunt the effect, and dietary salt undoes it. The response is to escalate the loop dose and route, then to block the nephron sequentially — adding a thiazide-type agent such as metolazone to attack the distal compensation, with close attention to potassium and magnesium. Adding acetazolamide to a loop diuretic improves decongestion in randomised data, and the sodium-glucose cotransporter-2 inhibitors add natriuresis and outcome benefit and increasingly belong in the regimen. Ultrafiltration is reserved for genuinely diuretic-refractory congestion; a randomised trial found it no better than stepped pharmacologic care and more prone to adverse events, so it is a tool for the refractory, not a first move.

The creatinine that rises for a good reason

Decongestion often nudges the creatinine up, and the instinct to stop is usually wrong. As you remove fluid, the blood haemoconcentrates and the neurohormonal axis activates, so creatinine drifts higher — pseudo-worsening renal function. When it happens in a patient who is still congested and genuinely decongesting, it is associated with good, not bad, outcomes, and the diuretic should continue. True worsening is different: it appears with signs of hypovolaemia, a falling filling pressure, or features of intrinsic injury, and it warrants reassessment. The skill is telling the benign rise from the dangerous one, and not abandoning effective decongestion because a number moved in the expected direction.

Where fluid and inotropes do and do not belong

The cardiorenal patient is usually wet, so fluid is rarely the answer and often the harm; reserve it for the genuinely under-filled, which in this population is uncommon. Inotropes and vasopressors belong to the low-output patient — cardiogenic shock with true forward failure — and not to the warm, congested majority. Over the longer arc, the treatment that helps both organs is guideline-directed heart-failure therapy: renin-angiotensin blockade, beta-blockade, mineralocorticoid antagonism, the SGLT2 inhibitors, and angiotensin-receptor-neprilysin inhibition. Starting a RAAS blocker commonly bumps the creatinine; a rise under about a third is expected and reflects the drug working on glomerular haemodynamics, not kidney injury, and is not a reason to stop.

Table 6.1 — The five cardiorenal syndromes

Table 6.2 — Forward failure versus venous congestion

Table 6.3 — Assessing congestion

Table 6.4 — Loop diuretic strategy

Table 6.5 — Diuretic resistance: cause and counter

Table 6.6 — True versus pseudo-worsening renal function

Clinical Reasoning

One triad per mechanism the narrative exposed: the physiology, why it matters, and the bedside move.

Safety & Evidence

Panel A — Red flags

Panel B — Never do

Pitfall 1 — Fluid for the congested kidney

Pitfall 2 — Stopping diuretics for pseudo-WRF

Pitfall 3 — Timid, oral diuretic dosing

Pitfall 4 — Missing forward failure

Pitfall 5 — Over-reacting to the RAAS bump

Graded statements (by evidence type)

Patient Decisions

Natural-frequency estimates for orientation, pooled from trials and cohorts; they vary with severity and setting. They size the cardiorenal decisions, expressed as how many of 100 comparable patients are affected.

Apply & Test

Paste-ready notes. Tick the boxes that apply and delete the rest; keep the congestion read and the decongestion target visible.

Template 1 — Cardiorenal congestion assessment and decongestion plan

• Cardiorenal type: ☐ 1 acute cardiorenal ☐ 2 chronic ☐ 3 renocardiac ☐ 4 chronic renocardiac ☐ 5 secondary.
• Profile: ☐ warm-and-congested ☐ cold-and-shocked (low output).
• Congestion read: ☐ JVP raised ☐ lung B-lines ☐ plethoric IVC ☐ VEXUS grade ___ ☐ oedema/ascites.
• AKI stage ___ ; baseline creatinine ___ , current ___ .
• Plan: IV loop diuretic ___ mg (≥ home-equivalent); spot urine sodium at 2 h target > 50–70 mmol/L.
• If low output: ☐ inotrope/perfusion first. If congested: ☐ decongest; ☐ no fluid.
• Guideline-directed therapy reviewed: ☐ RAAS/ARNI ☐ beta-blocker ☐ MRA ☐ SGLT2 inhibitor.

Template 2 — Diuretic response reassessment

• Loop dose/route given: ___ ; time ___ .
• 2-hour spot urine sodium: ___ mmol/L — ☐ adequate (> 50–70) ☐ poor (escalate).
• Urine output / weight change since: ___ ; congestion now: ☐ improving ☐ unchanged.
• If poor response: ☐ increase loop dose ☐ IV infusion ☐ add thiazide/metolazone ☐ add acetazolamide ☐ add/continue SGLT2 inhibitor.
• Creatinine trend: ___ — ☐ pseudo-WRF (still congested, decongesting) → continue ☐ true WRF (hypovolaemic/collapsing IVC) → ease off.
• Refractory despite escalation → ☐ consider ultrafiltration.